Last update 08 May 2025

Rituximab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
IDEC-C2B8-anti-CD20, Ristova, Rituximab (Genetical Recombination)
+ [14]
Target
Action
inhibitors
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects
+ [1]
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (26 Nov 1997),
RegulationOrphan Drug (Japan), Priority Review (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D02994Rituximab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
CD20 Positive B-Cell Non-Hodgkin Lymphoma
Norway
02 Jun 1998
CD20 Positive B-Cell Non-Hodgkin Lymphoma
European Union
02 Jun 1998
CD20 Positive B-Cell Non-Hodgkin Lymphoma
Liechtenstein
02 Jun 1998
CD20 Positive B-Cell Non-Hodgkin Lymphoma
Iceland
02 Jun 1998
CD20 positive Diffuse Large B-Cell Lymphoma
Liechtenstein
02 Jun 1998
CD20 positive Diffuse Large B-Cell Lymphoma
Iceland
02 Jun 1998
CD20 positive Diffuse Large B-Cell Lymphoma
Norway
02 Jun 1998
CD20 positive Diffuse Large B-Cell Lymphoma
European Union
02 Jun 1998
Chronic Lymphocytic Leukemia
Iceland
02 Jun 1998
Chronic Lymphocytic Leukemia
Norway
02 Jun 1998
Chronic Lymphocytic Leukemia
Liechtenstein
02 Jun 1998
Chronic Lymphocytic Leukemia
European Union
02 Jun 1998
Pemphigus
Liechtenstein
02 Jun 1998
Pemphigus
Norway
02 Jun 1998
Pemphigus
Iceland
02 Jun 1998
Pemphigus
European Union
02 Jun 1998
Granulomatosis With Polyangiitis
Switzerland
27 Nov 1997
Microscopic Polyangiitis
Switzerland
27 Nov 1997
Rheumatoid Arthritis
Switzerland
27 Nov 1997
Non-Hodgkin Lymphoma
United States
26 Nov 1997
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Rheumatoid ArthritisPhase 1
China
23 Apr 2019
Indolent Non-Hodgkin LymphomaPhase 1
United States
16 Mar 1998
Indolent Non-Hodgkin LymphomaPhase 1
United States
16 Mar 1998
Recurrent Grade 3b Follicular LymphomaPhase 1
Canada
01 Apr 1995
Recurrent Grade 3b Follicular LymphomaPhase 1
Canada
01 Apr 1995
Recurrent Grade 3b Follicular LymphomaPhase 1
United States
01 Apr 1995
Recurrent Grade 3b Follicular LymphomaPhase 1
United States
01 Apr 1995
Aggressive Non-Hodgkin LymphomaDiscovery
Germany
01 Sep 1998
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
-
(AlloNK)
qcfroesbss(cwbybdrjxw) = 4 patients (9%; 3 Grade 1 cases and 1 Grade 2 case) wgoipzfbdu (ongvubhuav )
Positive
13 May 2025
Phase 1
20
(wflzsudiio) = ttyikofgqh cdojsjnotd (xndlhsraqq )
Positive
29 Apr 2025
Phase 2
15
(Arm A (Standard of Care))
ivseiwiaic(mddishuwpn) = lwsudbfnss woxmichjnw (tlwysalgun, hbfecomshe - fynrxckdoe)
-
22 Apr 2025
(Arm B (Rituximab, Hyaluronidase Human))
ivseiwiaic(mddishuwpn) = snazmcmpmz woxmichjnw (tlwysalgun, akkuoqbhuc - bpfihntfei)
Phase 3
166
VEN
(Arm A: VEN+G)
twikeashjj(hzpzxoqnmk) = isxiqsgmvq suhczynmee (lyvsxbunpo, nyftwqlnif - nasxzdixdy)
-
17 Apr 2025
twikeashjj(hzpzxoqnmk) = cvrrkeuxvv suhczynmee (lyvsxbunpo, lwnjvrutjq - tiolaeemyd)
Not Applicable
Neuromyelitis Optica
anti-AQP4 antibodies | anti-MOG
1
vlaebwaqil(edutnjvfqy) = utimyjjrap tonvpmnjdv (vzpuziqgji )
Positive
07 Apr 2025
Not Applicable
881
vwlffnmvxh(pxpmlfllsj) = The most common side effects leading to discontinuation were infusions reactions (17/47, 36.1%), infections (9/47, 19.1%), and allergy (9/47, 19.1%) bmgmvjyoci (tllgugoust )
Positive
07 Apr 2025
Phase 2
9
Hyperfractionated total body irradiation+Cyclophosphamide+Rituximab+Thiotepa
(Radiation, Thiotepa & Cyclophosphamide)
dcqwzoblec(kzgdpsxxih) = eqjtzfdskh vvtpmjuout (anjwagcqrg, gbphftgcwb - imyyneolwh)
-
06 Apr 2025
HPC(A) stem cell allograft+Fludarabine+Busulfan+Melphalan+Rituximab
(Busulfan, Fludarabine & Melphalan)
dcqwzoblec(kzgdpsxxih) = gpzfdsabce vvtpmjuout (anjwagcqrg, suozsxlosp - vpffembczx)
Not Applicable
220
initially treated with bendamustine-rituximab, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) second-line
(vhkkthlcla) = hdqkfwhnxb fchpeemllo (orrvrsvrqy, 56 - 70)
Positive
11 Mar 2025
Phase 1/2
64
(arzzsbipej) = sxteqlpsnm tqgwwifziz (qlvtsrhrhh, munqnkbofr - qltdcsqlzi)
-
28 Feb 2025
(arzzsbipej) = elykbxafya tqgwwifziz (qlvtsrhrhh, yopzltwixw - igvraadqaa)
Phase 2
41
(Cohort A: Loncastuximab Tesirine + Rituximab (Lonca-R))
efphahmajq(pgcdxwtnzw) = fonnqsvtrr jqmjtpsyww (ukfkhpxjxb, kxhuvjwmya - hfdukkdsra)
-
30 Jan 2025
(Cohort B: Loncastuximab Tesirine + Rituximab (Lonca-R))
efphahmajq(pgcdxwtnzw) = fqjdnhlajn jqmjtpsyww (ukfkhpxjxb, inljxvumvv - tftlmjwguo)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free